A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports. Olaparib, a pill lacking the side effects of chemotherapy, can target an Achilles heel in prostate cancers with a weakness in their ability to repair damaged DNA.
from Top Health News -- ScienceDaily https://ift.tt/2YkR1PI
Subscribe to:
Post Comments (Atom)
Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO
However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...
-
The IT major further said the Ebit margin for the current quarter is expected to be between 20.5-21 per cent from Home Page https://ift.tt...
-
Here's a look at some of the companies whose shares are expected to trade actively in Friday's session - from Home Page http://bit...
-
Latest News LIVE updates: Prime Minister Narendra Modi will be on a day's visit to poll-bound Assam and West Bengal on February 7 to lay...
No comments:
Post a Comment